Cargando…

Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors

Novel therapies are undergoing clinical trials, for example, the Hsp90 inhibitor, XL888, in combination with BRAF inhibitors for the treatment of therapy‐resistant melanomas. Unfortunately, our data show that this combination elicits a heterogeneous response in a panel of melanoma cell lines includi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Azimi, Alireza, Caramuta, Stefano, Seashore‐Ludlow, Brinton, Boström, Johan, Robinson, Jonathan L, Edfors, Fredrik, Tuominen, Rainer, Kemper, Kristel, Krijgsman, Oscar, Peeper, Daniel S, Nielsen, Jens, Hansson, Johan, Egyhazi Brage, Suzanne, Altun, Mikael, Uhlen, Mathias, Maddalo, Gianluca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836539/ https://www.ncbi.nlm.nih.gov/pubmed/29507054 http://dx.doi.org/10.15252/msb.20177858

Ejemplares similares

Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells
por: Azimi, Alireza, et al.
Publicado: (2017)

Presence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanoma
por: Falkenius, Johan, et al.
Publicado: (2017)

Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status
por: Das, Ishani, et al.
Publicado: (2019)

Inhibiting insulin and mTOR signaling by afatinib and crizotinib combination fosters broad cytotoxic effects in cutaneous malignant melanoma
por: Das, Ishani, et al.
Publicado: (2020)

Silencing of CEBPB-AS1 modulates CEBPB expression and resensitizes BRAF-inhibitor resistant melanoma cells to vemurafenib
por: Vidarsdottir, Linda, et al.
Publicado: (2020)

PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma
por: Vidarsdottir, Linda, et al.
Publicado: (2021)

ΔNp73 regulates the expression of the multidrug-resistance genes ABCB1 and ABCB5 in breast cancer and melanoma cells - a short report
por: Sakil, Habib A. M., et al.
Publicado: (2017)

Proteomics analysis of melanoma metastases: association between S100A13 expression and chemotherapy resistance
por: Azimi, A, et al.
Publicado: (2014)

ROCK1 is a potential combinatorial drug target for BRAF mutant melanoma
por: Smit, Marjon A, et al.
Publicado: (2014)

Extracellular microvesicle microRNAs as predictive biomarkers for targeted therapy in metastastic cutaneous malignant melanoma
por: Svedman, Fernanda Costa, et al.
Publicado: (2018)

AXL and CAV-1 play a role for MTH1 inhibitor TH1579 sensitivity in cutaneous malignant melanoma
por: Das, Ishani, et al.
Publicado: (2020)

BRAF(V600E) Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts
por: Kemper, Kristel, et al.
Publicado: (2016)

A Portable, Negative-Pressure Actuated, Dynamically Tunable Microfluidic Droplet Generator
por: Trossbach, Martin, et al.
Publicado: (2022)

Enhanced validation of antibodies for research applications
por: Edfors, Fredrik, et al.
Publicado: (2018)

Proliferation and Immune Response Gene Signatures Associated with Clinical Outcome to Immunotherapy and Targeted Therapy in Metastatic Cutaneous Malignant Melanoma
por: Costa Svedman, Fernanda, et al.
Publicado: (2022)

MEK + CDK4 a regimen for non-BRAF V6000 melanoma
por: Sosman, Jeff
Publicado: (2015)

CDK12 is hyperactivated and a synthetic-lethal target in BRAF-mutated melanoma
por: Houles, Thibault, et al.
Publicado: (2022)

Immediate Adaptation Analysis Implicates BCL6 as an EGFR-TKI Combination Therapy Target in NSCLC
por: Zhou Tran, Yan, et al.
Publicado: (2020)

CDK4 phosphorylation status and rational use for combining CDK4/6 and BRAF/MEK inhibition in advanced thyroid carcinomas
por: Pita, Jaime M., et al.
Publicado: (2023)

O6-methylguanine-DNA methyltransferase activities in biopsies of human melanoma tumours.
por: Egyházi, S., et al.
Publicado: (1995)

Immunotherapeutic targeting of HSP90 client proteins in BRAF-inhibitor resistant melanoma
por: Fecek, Ronald J, et al.
Publicado: (2015)

CopywriteR: DNA copy number detection from off-target sequence data
por: Kuilman, Thomas, et al.
Publicado: (2015)

Solid-phase cloning for high-throughput assembly of single and multiple DNA parts
por: Lundqvist, Magnus, et al.
Publicado: (2015)

Breeze 2.0: an interactive web-tool for visual analysis and comparison of drug response data
por: Potdar, Swapnil, et al.
Publicado: (2023)

Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts
por: Kemper, Kristel, et al.
Publicado: (2015)

Addressing the Protease Bias in Quantitative Proteomics
por: Woessmann, Jakob, et al.
Publicado: (2022)

Dabrafenib inhibits the growth of BRAF‐WT cancers through CDK16 and NEK9 inhibition
por: Phadke, Manali, et al.
Publicado: (2017)

CDK11 Loss Induces Cell Cycle Dysfunction and Death of BRAF and NRAS Melanoma Cells
por: Ahmed, Rehana L., et al.
Publicado: (2019)

Enhancing Adoptive Cell Transfer with Combination BRAF-MEK and CDK4/6 Inhibitors in Melanoma
por: Lau, Peter Kar Han, et al.
Publicado: (2021)

Ubiquitination and adaptive responses to BRAF inhibitors in Melanoma
por: Saei, Azad, et al.
Publicado: (2018)

Targeted proteomics using stable isotope labeled protein fragments enables precise and robust determination of total apolipoprotein(a) in human plasma
por: Hober, Andreas, et al.
Publicado: (2023)

Adaptive Responses as Mechanisms of Resistance to BRAF Inhibitors in Melanoma
por: Saei, Azad, et al.
Publicado: (2019)

Differential Regulation of G1 CDK Complexes by the Hsp90-Cdc37 Chaperone System
por: Hallett, Stephen T., et al.
Publicado: (2017)

Next generation plasma proteome profiling to monitor health and disease
por: Zhong, Wen, et al.
Publicado: (2021)

XenofilteR: computational deconvolution of mouse and human reads in tumor xenograft sequence data
por: Kluin, Roelof J. C., et al.
Publicado: (2018)

MEK/CDK4,6 co-targeting is effective in a subset of NRAS, BRAF and ‘wild type’ melanomas
por: Posch, Christian, et al.
Publicado: (2018)

CDK-Dependent Hsp70 Phosphorylation Controls G1 Cyclin Abundance and Cell-Cycle Progression
por: Truman, Andrew W., et al.
Publicado: (2012)

FGFR4 phosphorylates MST1 to confer breast cancer cells resistance to MST1/2-dependent apoptosis
por: Turunen, S. Pauliina, et al.
Publicado: (2019)

Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma
por: Tholander, Bengt, et al.
Publicado: (2020)

HSP10 as a Chaperone for Neurodegenerative Amyloid Fibrils
por: Larsson, Johan N. K., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lt43lj8svft6gbt7hl88cnqpme